Immunotherapy

What is Immunotherapy?

Immunotherapy is a treatment that activates or suppresses the immune system and by that assist the immune system in attacking the tumor. This type of treatment is very different from chemotherapy, for example, which directly attacks the cancerous cells but unfortunately also damages healthy tissues.

The immune system has “immune barriers” which serve to regulate the immune system and prevent it from attacking the body. In cancer these functions are readily activated and as a result, the immune system ceases to attack cancerous cells, enabling the tumor to grow and proliferate in the body.

Barriers known as PD-L1, PD-1 and CTLA-4 are found on T-cells and cancer cells. For example, the biological drug Opidivo® (generic name: Nivolumab) activates the immune system against the tumor.

Immunotherapy is a revolutionary strategy, and one of the most widely studied worldwide for its application to numerous types of cancer and various stages of the disease’s development. Treatment is generally provided in the form of an intravenous infusion.

Immunotherapy drugs examples:

PD-1 drugs:
• Keytruda® (Pembrolizumab)
• Opdivo® (Nivolumab)

PD-L1 drugs:
• Tecentriq® (Atezolizumab)
• Imfinzi® (Durvalumab)

What are the most common side effects?

Reaction of the skin

Redness, blisters and dryness. The skin can become sensitive when exposed to sunlight. Inflammation around the fingernails can occur and cause pain when dressing, for example.

Flu-like symptoms

Fatigue, fever, chills, nausea, vomiting, dizziness, body pain and high or low blood pressure

Other side effects may be:

Muscle Pain
Difficulties in breathing
Swelling of the legs
Sinus congestion
Headaches
Weight gain due to accumulation of fluids
Diarrhea
Hormonal changes
Cough

And there could be more

Most of the side effects will disappear at the end of the immunotherapy treatment, but some can occur months and even years later.

It is important to consult with your healthcare professional about coping with side effects.

TRIAL-IN-Pharma offers a unique, personalized research and analysis for patients with metastatic cancer and brain tumors, which reveals innovative and advanced oncologic treatments around the world and support the process of achieving them.

Read our publications on immunotherapy and other innovative treatments for stage 4 metastatic cancer:

Ovarian Cancer – Mirvetuximab Soravtansine Yields Benefit

Background Patients with platinum-resistant ovarian cancer have limited therapeutic options available to them. Treatment is largely comprised of chemotherapy, which is known to have limited

סרטן ריאה – טוריפאלימאב עם כימו' עדיף על כימו' לבד

Lung cancer – Toripalimab Plus Chemo is Better than Chemo Alone

Background According to data from the CHOICE-1 trial, Toripalimab (anti–PD-1) in combination with chemotherapy showed significant improvement in the length of time until progression of

גליובלסטומה, GBM - תוצאות מבטיחות עם VT1021

Glioblastoma (GBM) – VT1021 Demonstrates Promising Results

Overview Glioblastoma, GBM, is a type of cancer that affects the central nervous system. It stems from astrocytes, which are special cells that support the

Ovarian Cancer – A New Standard of Care?

Overview Serous ovarian cancer is a relatively uncommon tumor that could be quite challenging to manage, especially when it’s recurrent. Among women, ovarian cancer is

Lung cancer – A novel treatment with Sugemalimab

Overview Smoking tobacco products has made lung cancer one of the most common tumors in the world. The prevalence of lung cancer is especially predominant

New Biological Drug for Melanoma – Relatlimab

Overview Advanced Melanoma is a challenging type of cancer to deal with, especially when it spreads to multiple sites in the body, metastasizes. Moreover, the

Cervical Cancer – New drug combination: Balstilimab Plus Zalifrelimab

Overview Advanced cases of cervical cancer pose a challenge for physicians to treat. Once the cancer cells have spread to other tissues, procedures such as

Lung cancer – Tiragolumab Plus Atezolizumab Survival

Overview Lung cancer is a very challenging condition to manage, especially when discovered late. The incredibly high incidence of lung cancer – mostly caused by

Breast Cancer - NERLYNX (Neratinib) for Leptomeningeal Metastases

Breast Cancer – NERLYNX for Leptomeningeal Metastases

Overview The spread of cancer cells beyond the original site of the tumor is a very challenging process. When cancer cells of the breast are

Glioblastoma – A New Combination Treatment You Need to Know

Overview Glioblastoma, or GBM, is an aggressive type of tumor that occurs in the brain. Due to the location of this tumor and the limited

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Novel Drug Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer: Pyrotinib and Etoposide

Encouraging News in Advanced Breast Cancer!

Success Story – Where There’s a Will, There’s a Way! 🌟

Encouraging News in Metastatic Breast Cancer Treatment 🎯

Encouraging News in Bladder Cancer Treatment 🎯

A Story of Hope, Persistence, and an Moving Achievement for Daria, a 5-year-old Girl from Poland Facing a Brain Tumor

Home » Immunotherapy » Page 2

Ovarian Cancer – Mirvetuximab Soravtansine Yields Benefit

Background

Patients with platinum-resistant ovarian cancer have limited therapeutic options available to them. Treatment is largely comprised of chemotherapy, which is known to have limited efficacy where just 4% and 13% will benefit and substantial toxicity.

No biomarker-driven approaches have been indicated for this population.

Clinically meaningful antitumor activity and an acceptable safety profile were seen with the use of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer harboring high folate receptor–alpha (FRα) expression, according to the results of the phase 3 SORAYA trial (NCT04296890) presented during the The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer.

About the Study in ovarian cancer

The global, single-arm, phase 3 SORAYA trial enrolled patients with platinum-resistant ovarian cancer who were treated with 1 to 3 prior regimens and experienced recurrence within 6 months after the last platinum dose they had received.

To be eligible for enrollment, patients needed to have high-grade serous histology and have received prior Avastin.

Patients needed to have tumors that demonstrated FRα-high with immunohistochemistry PS2+ scoring.

Study Results – Patients with Platinum-Resistant Ovarian Cancer Harboring High Folate Receptor–Alpha (FRα) Expression

This antibody-drug conjugate (ADC) elicited a response rate (percentage of patients whose tumors decreased) of 32.4% in the patient population (n = 105).

Among the 34 responders, 5 patients achieved a complete remission
29 patients experienced a partial response (percentage of patients whose tumors decreased between 30-50%)
7% of patients achieved stable disease
0% experienced disease progression
The median duration of response was 6.9 months with the drug
Moreover, the median progression-free survival (The time it took until the disease progressed under the treatment) with Mirvetuximab Soravtansine was 4.3 months.

What is Mirvetuximab Soravtansine?

Mirvetuximab Soravtansine is an antibody-drug conjugate (ADC) comprised of an FRα-binding antibody, a cleavable linker, and maytansinoid DM4.

Findings from a pooled analysis of prior studies that examined the ADC in 70 patients with FRα-high, platinum-resistant ovarian cancer who previously received 1 to 3 therapies, which included Avastin showed:

Response Rate of 31.4%
Median Duration of Response of 7.8 months
Median Time Until Disease Progression of 4.4 months

Side Effects

Most side effects were low-grade, reversible ocular and gastrointestinal events.

Serious treatment-related side effects were experienced by 8% of patients.

A total of 7 patients discontinued treatment with the ADC because of toxicity.

Takeaway Message for ovarian cancer patients

Phase 3 SOROYA trial revealed promising response rates with Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer and high folate receptor–alpha (FRα) expression.

Talk to us so see if we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

Immunotherapy

What is Immunotherapy?

What are the most common side effects?

Reaction of the skin

Flu-like symptoms

Other side effects may be:

Read our publications on immunotherapy and other innovative treatments for stage 4 metastatic cancer:

קטגוריות המאמרים

Tags

Ovarian Cancer – Mirvetuximab Soravtansine Yields Benefit

Background

About the Study in ovarian cancer

Study Results – Patients with Platinum-Resistant Ovarian Cancer Harboring High Folate Receptor–Alpha (FRα) Expression

What is Mirvetuximab Soravtansine?

Side Effects

Takeaway Message for ovarian cancer patients

Talk to us so see if we can help you to actually get the most advanced treatments

קטגוריות המאמרים

Tags